The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Diabetic Therapeutic Drugs-Global Market Insights and Sales Trends 2025

Diabetic Therapeutic Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1812257

No of Pages : 111

Ask Your Query
Synopsis
The global Diabetic Therapeutic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Diabetic Therapeutic Drugs in various end use industries. The expanding demands from the Type 1 Diabetes, Type 2 Diabetes and Gestational Diabetes,, are propelling Diabetic Therapeutic Drugs market. Insulin Therapies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-Insulin Therapies segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diabetic Therapeutic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diabetic Therapeutic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diabetic Therapeutic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diabetic Therapeutic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diabetic Therapeutic Drugs covered in this report include AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi, Pfizer, Novartis, Perle Biosciences and Sun Pharma, etc.
The global Diabetic Therapeutic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Eli Lilly
Merck
Novo Nordisk
Sanofi
Pfizer
Novartis
Perle Biosciences
Sun Pharma
Takeda Pharmaceuticals
F. Hoffmann-La Roche
Belrose Pharma
Mitsubishi Tanabe Pharma
Dong-A ST
Eisai
Arbutus Biopharma
Global Diabetic Therapeutic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diabetic Therapeutic Drugs market, Segment by Type:
Insulin Therapies
Non-Insulin Therapies
Global Diabetic Therapeutic Drugs market, by Application
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Diabetic Therapeutic Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Diabetic Therapeutic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Diabetic Therapeutic Drugs Market Overview
1.1 Diabetic Therapeutic Drugs Product Overview
1.2 Diabetic Therapeutic Drugs Market Segment by Type
1.2.1 Insulin Therapies
1.2.2 Non-Insulin Therapies
1.3 Global Diabetic Therapeutic Drugs Market Size by Type
1.3.1 Global Diabetic Therapeutic Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Diabetic Therapeutic Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Diabetic Therapeutic Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Diabetic Therapeutic Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Diabetic Therapeutic Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Diabetic Therapeutic Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Diabetic Therapeutic Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Diabetic Therapeutic Drugs Sales Breakdown by Type (2018-2023)
2 Global Diabetic Therapeutic Drugs Market Competition by Company
2.1 Global Top Players by Diabetic Therapeutic Drugs Sales (2018-2023)
2.2 Global Top Players by Diabetic Therapeutic Drugs Revenue (2018-2023)
2.3 Global Top Players by Diabetic Therapeutic Drugs Price (2018-2023)
2.4 Global Top Manufacturers Diabetic Therapeutic Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Diabetic Therapeutic Drugs Market Competitive Situation and Trends
2.5.1 Diabetic Therapeutic Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Diabetic Therapeutic Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diabetic Therapeutic Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Diabetic Therapeutic Drugs Market
2.8 Key Manufacturers Diabetic Therapeutic Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Diabetic Therapeutic Drugs Status and Outlook by Region
3.1 Global Diabetic Therapeutic Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Diabetic Therapeutic Drugs Historic Market Size by Region
3.2.1 Global Diabetic Therapeutic Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Diabetic Therapeutic Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Diabetic Therapeutic Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Diabetic Therapeutic Drugs Forecasted Market Size by Region
3.3.1 Global Diabetic Therapeutic Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Diabetic Therapeutic Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Diabetic Therapeutic Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Diabetic Therapeutic Drugs by Application
4.1 Diabetic Therapeutic Drugs Market Segment by Application
4.1.1 Type 1 Diabetes
4.1.2 Type 2 Diabetes
4.1.3 Gestational Diabetes
4.2 Global Diabetic Therapeutic Drugs Market Size by Application
4.2.1 Global Diabetic Therapeutic Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Diabetic Therapeutic Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Diabetic Therapeutic Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Diabetic Therapeutic Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Diabetic Therapeutic Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Diabetic Therapeutic Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Diabetic Therapeutic Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Diabetic Therapeutic Drugs Sales Breakdown by Application (2018-2023)
5 North America Diabetic Therapeutic Drugs by Country
5.1 North America Diabetic Therapeutic Drugs Historic Market Size by Country
5.1.1 North America Diabetic Therapeutic Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Diabetic Therapeutic Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Diabetic Therapeutic Drugs Sales in Value by Country (2018-2023)
5.2 North America Diabetic Therapeutic Drugs Forecasted Market Size by Country
5.2.1 North America Diabetic Therapeutic Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Diabetic Therapeutic Drugs Sales in Value by Country (2024-2029)
6 Europe Diabetic Therapeutic Drugs by Country
6.1 Europe Diabetic Therapeutic Drugs Historic Market Size by Country
6.1.1 Europe Diabetic Therapeutic Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Diabetic Therapeutic Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Diabetic Therapeutic Drugs Sales in Value by Country (2018-2023)
6.2 Europe Diabetic Therapeutic Drugs Forecasted Market Size by Country
6.2.1 Europe Diabetic Therapeutic Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Diabetic Therapeutic Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Diabetic Therapeutic Drugs by Region
7.1 Asia-Pacific Diabetic Therapeutic Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Diabetic Therapeutic Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Diabetic Therapeutic Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Diabetic Therapeutic Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Diabetic Therapeutic Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Diabetic Therapeutic Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Diabetic Therapeutic Drugs Sales in Value by Region (2024-2029)
8 Latin America Diabetic Therapeutic Drugs by Country
8.1 Latin America Diabetic Therapeutic Drugs Historic Market Size by Country
8.1.1 Latin America Diabetic Therapeutic Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Diabetic Therapeutic Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Diabetic Therapeutic Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Diabetic Therapeutic Drugs Forecasted Market Size by Country
8.2.1 Latin America Diabetic Therapeutic Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Diabetic Therapeutic Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Diabetic Therapeutic Drugs by Country
9.1 Middle East and Africa Diabetic Therapeutic Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Diabetic Therapeutic Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Diabetic Therapeutic Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Diabetic Therapeutic Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Diabetic Therapeutic Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Diabetic Therapeutic Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Diabetic Therapeutic Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AstraZeneca
10.1.1 AstraZeneca Company Information
10.1.2 AstraZeneca Introduction and Business Overview
10.1.3 AstraZeneca Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AstraZeneca Diabetic Therapeutic Drugs Products Offered
10.1.5 AstraZeneca Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Information
10.2.2 Eli Lilly Introduction and Business Overview
10.2.3 Eli Lilly Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly Diabetic Therapeutic Drugs Products Offered
10.2.5 Eli Lilly Recent Development
10.3 Merck
10.3.1 Merck Company Information
10.3.2 Merck Introduction and Business Overview
10.3.3 Merck Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck Diabetic Therapeutic Drugs Products Offered
10.3.5 Merck Recent Development
10.4 Novo Nordisk
10.4.1 Novo Nordisk Company Information
10.4.2 Novo Nordisk Introduction and Business Overview
10.4.3 Novo Nordisk Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novo Nordisk Diabetic Therapeutic Drugs Products Offered
10.4.5 Novo Nordisk Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Introduction and Business Overview
10.5.3 Sanofi Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Diabetic Therapeutic Drugs Products Offered
10.5.5 Sanofi Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Information
10.6.2 Pfizer Introduction and Business Overview
10.6.3 Pfizer Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pfizer Diabetic Therapeutic Drugs Products Offered
10.6.5 Pfizer Recent Development
10.7 Novartis
10.7.1 Novartis Company Information
10.7.2 Novartis Introduction and Business Overview
10.7.3 Novartis Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novartis Diabetic Therapeutic Drugs Products Offered
10.7.5 Novartis Recent Development
10.8 Perle Biosciences
10.8.1 Perle Biosciences Company Information
10.8.2 Perle Biosciences Introduction and Business Overview
10.8.3 Perle Biosciences Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Perle Biosciences Diabetic Therapeutic Drugs Products Offered
10.8.5 Perle Biosciences Recent Development
10.9 Sun Pharma
10.9.1 Sun Pharma Company Information
10.9.2 Sun Pharma Introduction and Business Overview
10.9.3 Sun Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Sun Pharma Diabetic Therapeutic Drugs Products Offered
10.9.5 Sun Pharma Recent Development
10.10 Takeda Pharmaceuticals
10.10.1 Takeda Pharmaceuticals Company Information
10.10.2 Takeda Pharmaceuticals Introduction and Business Overview
10.10.3 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Takeda Pharmaceuticals Diabetic Therapeutic Drugs Products Offered
10.10.5 Takeda Pharmaceuticals Recent Development
10.11 F. Hoffmann-La Roche
10.11.1 F. Hoffmann-La Roche Company Information
10.11.2 F. Hoffmann-La Roche Introduction and Business Overview
10.11.3 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 F. Hoffmann-La Roche Diabetic Therapeutic Drugs Products Offered
10.11.5 F. Hoffmann-La Roche Recent Development
10.12 Belrose Pharma
10.12.1 Belrose Pharma Company Information
10.12.2 Belrose Pharma Introduction and Business Overview
10.12.3 Belrose Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Belrose Pharma Diabetic Therapeutic Drugs Products Offered
10.12.5 Belrose Pharma Recent Development
10.13 Mitsubishi Tanabe Pharma
10.13.1 Mitsubishi Tanabe Pharma Company Information
10.13.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
10.13.3 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Mitsubishi Tanabe Pharma Diabetic Therapeutic Drugs Products Offered
10.13.5 Mitsubishi Tanabe Pharma Recent Development
10.14 Dong-A ST
10.14.1 Dong-A ST Company Information
10.14.2 Dong-A ST Introduction and Business Overview
10.14.3 Dong-A ST Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Dong-A ST Diabetic Therapeutic Drugs Products Offered
10.14.5 Dong-A ST Recent Development
10.15 Eisai
10.15.1 Eisai Company Information
10.15.2 Eisai Introduction and Business Overview
10.15.3 Eisai Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Eisai Diabetic Therapeutic Drugs Products Offered
10.15.5 Eisai Recent Development
10.16 Arbutus Biopharma
10.16.1 Arbutus Biopharma Company Information
10.16.2 Arbutus Biopharma Introduction and Business Overview
10.16.3 Arbutus Biopharma Diabetic Therapeutic Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Arbutus Biopharma Diabetic Therapeutic Drugs Products Offered
10.16.5 Arbutus Biopharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Diabetic Therapeutic Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Diabetic Therapeutic Drugs Industrial Chain Analysis
11.4 Diabetic Therapeutic Drugs Market Dynamics
11.4.1 Diabetic Therapeutic Drugs Industry Trends
11.4.2 Diabetic Therapeutic Drugs Market Drivers
11.4.3 Diabetic Therapeutic Drugs Market Challenges
11.4.4 Diabetic Therapeutic Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Diabetic Therapeutic Drugs Distributors
12.3 Diabetic Therapeutic Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock